Raymond James & Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Raymond James & Associates’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,250	Closed	-$4.75K	–	4091
2024 Q2	$4.75K	Sell	13,250 -700	-5%	-$378	﹤0.01%	3944
2024 Q1	$9.35K	Buy	+13,950	New	+$10.1K	﹤0.01%	3901
2021 Q4	–	Sell	-14,585	Closed	-$131K	–	4268
2021 Q3	$131K	Sell	14,585 -90,650	-86%	-$896K	﹤0.01%	3782
2021 Q2	$1.26M	Buy	105,235 +10,115	+11%	+$115K	﹤0.01%	2433
2021 Q1	$1.19M	Buy	95,120 +17,100	+22%	+$230K	﹤0.01%	2385
2020 Q4	$1.22M	Buy	+78,020	New	+$914K	﹤0.01%	2209
2018 Q2	–	Sell	-13,627	Closed	-$259K	–	3660
2018 Q1	$259K	Buy	+13,627	New	+$291K	﹤0.01%	2986

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Raymond James & Associates's SGMO Position: Q3 2024 in Review

Raymond James & Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 13,250 shares — an estimated $4.75K sold.

Raymond James & Associates first reported a position in SGMO in Q1 2018 and held it in 7 quarters. The position peaked at $1.26M in Q2 2021. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

Raymond James & Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
Raymond James & Associates sold 13,250 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $4.75K.
Raymond James & Associates first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 7 quarters.
Raymond James & Associates's SANGAMO THERAPEUTICS INC position peaked at $1.26M in Q2 2021.
103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.